HT
KALV

HAP Trading’s KalVista Pharmaceuticals KALV Stock Holding History

HAP Trading’s Portfolio KALV Stock Details KALV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		$76.5K Buy
+90,000
New +$1.24M 0.01% 540

Other funds holding KALV

VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

HAP Trading's KALV Position: Q3 2025 in Review

HAP Trading opened a new position in KalVista Pharmaceuticals (KALV) in Q3 2025: 31,219 shares worth $380K. The stake represents 0.03% of the portfolio and ranks #298 among its holdings.

145 funds tracked by Wall St. Rank hold KALV as of Q3 2025.

  • HAP Trading held 31,219 shares of KalVista Pharmaceuticals worth $380K as of Q3 2025.
  • KalVista Pharmaceuticals was a new HAP Trading position in Q3 2025.
  • KalVista Pharmaceuticals made up 0.03% of HAP Trading's portfolio in Q3 2025, its #298 holding.
  • 145 funds tracked by Wall St. Rank held KalVista Pharmaceuticals as of Q3 2025.

Based on HAP Trading's 13F filing for Q3 2025, filed 12 Nov 2025.